Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed some of the first robust laboratory models of a ...

The Cambridge research institute launched nearly two years ago with $500 million to support scientific research and ...

Cathie Wood's Ark Invest sold shares of five biotech and healthcare companies in recent trades. She also offloaded over 1.1 ...

Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...

Cathy Tie, who launched her first biotech in SF's IndieBio, now leads Manhattan Genomics in controversial push to edit human ...

VEXAS syndrome is an a confounding adult-onset inflammatory disease first described in 2020, which affects 1 in 4,000 men ...

Classical CRISPR systems use molecular scissors to snip through DNA ... the first reports emerged about a mysterious ...

Cathie Wood, head of Ark Investment Management, does not hesitate to sell and pocket profits when her high-conviction names ...

The COVID-19 pandemic is inflicting high and rising human costs worldwide, and the necessary protection measures are severely impacting economic activity. As a result of the pandemic, the global ...